263 related articles for article (PubMed ID: 21608333)
1. National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel.
Waisbourd M; Goldstein M; Loewenstein A
Isr Med Assoc J; 2011 Mar; 13(3):141-6. PubMed ID: 21608333
[TBL] [Abstract][Full Text] [Related]
2. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
3. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.
Cheung CS; Wong AW; Lui A; Kertes PJ; Devenyi RG; Lam WC
Ophthalmology; 2012 Aug; 119(8):1609-14. PubMed ID: 22480743
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.
Pece A; Isola V; Piermarocchi S; Calori G
Br J Ophthalmol; 2011 Jan; 95(1):56-68. PubMed ID: 20601660
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
10. Anti-VEGF in treatment of central retinal vein occlusion.
Lazić R; Boras I; Vlasić M; Gabrić N; Tomić Z
Coll Antropol; 2010 Apr; 34 Suppl 2():69-72. PubMed ID: 21305727
[TBL] [Abstract][Full Text] [Related]
11. Retinal artery occlusion following intravitreal anti-VEGF therapy.
von Hanno T; Kinge B; Fossen K
Acta Ophthalmol; 2010 Mar; 88(2):263-6. PubMed ID: 19416108
[TBL] [Abstract][Full Text] [Related]
12. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
13. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
Matsumoto Y; Freund KB; Peiretti E; Cooney MJ; Ferrara DC; Yannuzzi LA
Retina; 2007; 27(4):426-31. PubMed ID: 17420693
[TBL] [Abstract][Full Text] [Related]
14. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.
Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
Retina; 2007; 27(4):419-25. PubMed ID: 17420692
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravitreal anti-vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion.
Drechsler F; Köferl P; Hollborn M; Wiedemann P; Bringmann A; Kohen L; Rehak M
Ophthalmic Res; 2012; 47(3):157-62. PubMed ID: 22116547
[TBL] [Abstract][Full Text] [Related]
19. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
[TBL] [Abstract][Full Text] [Related]
20. Survey: technique of performing intravitreal injection among members of the Brazilian Retina and Vitreous Society (SBRV).
Shiroma HF; Farah ME; Takahashi WY; Gomes AM; Goldbaum M; Rodrigues EB
Arq Bras Oftalmol; 2015; 78(1):32-5. PubMed ID: 25714535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]